{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:05:39Z","timestamp":1792076739640,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["223045\/Z\/21\/Z"],"award-info":[{"award-number":["223045\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P027989\/1"],"award-info":[{"award-number":["MR\/P027989\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pt.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T08:09:54Z","timestamp":1708070994000},"page":"211-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A promising pipeline of preclinical drug candidates for leishmaniasis and chronic Chagas\u2019 disease"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-0460","authenticated-orcid":false,"given":"Manuel","family":"Saldivia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-2694","authenticated-orcid":false,"given":"Ana Paula C.A.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-3766","authenticated-orcid":false,"given":"Jeremy C.","family":"Mottram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2024.02.002_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/acsinfecdis.8b00298","article-title":"Drug discovery for kinetoplastid diseases: Future Directions","volume":"5","author":"Rao","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2024.02.002_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2024.02.002_bb0015","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2024.02.002_bb0020","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.adh0614","article-title":"Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections","volume":"380","author":"Rao","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.pt.2024.02.002_bb0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pt.2024.02.002_bb0030","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2024.02.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg8105","article-title":"Short-course combination treatment for experimental chronic Chagas disease","volume":"15","author":"Gonz\u00e1lez","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2024.02.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh9902","article-title":"DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1","volume":"15","author":"Braillard","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2024.02.002_bb0045","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/1873-3468.13868","article-title":"The cytochrome bc1 complex as an antipathogenic target","volume":"594","author":"Fisher","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pt.2024.02.002_bb0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/acsinfecdis.9b00426","article-title":"The Qi Site of cytochrome b is a promiscuous drug target in Trypanosoma cruzi and Leishmania donovani","volume":"6","author":"Wall","year":"2020","journal-title":"ACS Infect. Dis."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492224000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492224000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:42:27Z","timestamp":1761464547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492224000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1471492224000278"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2024.02.002","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A promising pipeline of preclinical drug candidates for leishmaniasis and chronic Chagas\u2019 disease","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}